(Press-News.org) DURHAM, N.C. – Among patients with mild or no cognitive impairment, brain scans using a new radioactive dye can detect early evidence of Alzheimer's disease that may predict future decline, according to a multi-center study led by researchers at Duke University Medical Center.
The finding is published online July 11, 2012, in the journal Neurology, the medical journal of the American Academy of Neurology. It expands on smaller studies demonstrating that early detection of tell-tale plaques could be a predictive tool to help guide care and treatment decisions for patients with Alzheimer's disease.
"Even at a short follow-up of 18 months we can see how the presence of amyloid plaques affects cognitive function," said P. Murali Doraiswamy, M.D., professor of psychiatry at Duke who co-led the study with R. Edward Coleman, M.D., professor of radiology at Duke . "Most people who come to the doctor with mild impairment really want to know the short-term prognosis and potential long-term effect."
Doraiswamy said such knowledge also has some pitfalls. There is no cure for Alzheimer's disease, which afflicts 5.4 million people in the United States and is the sixth-leading cause of death among U.S. adults. But he said numerous drugs are being investigated, and identifying earlier disease would improve research into their potential benefits and speed new discoveries, while also enhancing care and treatment of current patients.
In the Neurology study, 151 people who had enrolled in a multi-center test of a new radioactive dye called florbetapir (Amyvid) were recruited to participate in a 36-month analysis. Of those participants, 69 had normal cognitive function at the start of the study, 51 had been diagnosed with mild impairment, and 31 had Alzheimer's dementia.
All completed cognitive tests and underwent a brain scan using Positron Emission Tomography, or PET imaging. The technology uses radioactive tracers designed to highlight specific tissue to create a three-dimensional picture of an organ or a biological function.
The dye used in the study, florbetapir, was recently approved by the U.S. Food and Drug Administration for PET imaging of the brain to estimate beta-amyloid plaque density in patients who are being evaluated for cognitive impairment. It binds to the amyloid plaques that characterize Alzheimer's disease, providing a window into the brain to see if the plaques have formed, and how extensively.
Patients in the study were reassessed with additional cognitive exams at 18 months and 36 months. At the 18-month point, patients with mild cognitive impairment who had PET evidence of plaque at the trial's start worsened to a great degree on cognitive tests than patients who had no evidence of plaque at the trial's start. Twenty-nine percent of the plaque-positive patients in this group developed Alzheimer's dementia, compared to 10 percent who started with no plaque.
Cognitively normal patients with a plaque-positive PET scan at the start of the study also showed more mental decline at 18 months compared to those who were negative for plaque.
The study additionally found that people with negative scans reversed from minimally impaired to normal more often than people with positive PET scan, suggesting test anxiety or concentration problems could have affected their initial performance.
"For the most part we have been blind about who would progress and who wouldn't, so this approach is a step toward having a biomarker that predicts risk of decline in people who are experiencing cognitive impairment," Doraiswamy said.
He said the study's results provide initial data that needs to be verified by additional research. Final, 36-month data from the study has been completed and will be presented at the Alzheimer's Association International Conference this week in Vancouver, Canada. Doraiswamy also cautioned that florbetapir is currently not approved to predict the development of dementia or other neurologic conditions and stressed that it should not be used as a screening tool in otherwise normal or minimally impaired people. Likewise, a positive scan is not necessarily diagnostic for Alzheimer's by itself.
INFORMATION:
In addition to Doraiswamy and Coleman (who died in June), study authors included; Reisa A. Sperling and Keith A. Johnson of Massachusetts General Hospital, Boston Medical School; Eric M. Reiman of Banner Alzheimer's Institute; Mat D. Davis of the University of Pennsylvania; Michael Grundman of Global R&D Partners and the University of California, San Diego; Marwan N. Sabbagh of Banner-Sun Health Research Institute; Carl H. Sadowsky of Nova SE University; Adam S. Fleisher of Banner Alzheimer's Institute and UCSD; and Alan Carpenter, Christopher M. Clark (deceased), Abhinay D. Joshi, Mark A. Mintun, Daniel M. Skovronsky, and Michael J. Pontecorvo of Avid Radiopharmaceuticals.
The study was funded by Eli Lilly/Avid Radiopharmaceuticals, which markets florbetapir and conducted by Avid and the AV45-A11 study group, a consortium of Alzheimer's clinical research centers. Doraiswamy receives advisory and speaker fees from Lilly/Avid, as well as other companies, and owns shares in Sonexa and Clarimedix.
Alzheimer's plaques in PET brain scans identify future cognitive decline
2012-07-12
ELSE PRESS RELEASES FROM THIS DATE:
Decline of immune system with aging may have a genetic cause
2012-07-12
BETHESDA, MD – July 11, 2012 -- Important insights that explain why our ability to ward off infection declines with age are published in a new research report in the July 2012 issue of the Genetics Society of America's journal, GENETICS (http://www.genetics.org/). A team of U.S. scientists identified genes responsible for this decline by examining fruit flies – a model organism often used to study human biology in an experimentally tractable system – at different stages of their lives. They found that a completely different set of genes is responsible for warding off infection ...
Stanford scientists identify potential target for treating major symptom of depression
2012-07-12
STANFORD, Calif. — Stanford University School of Medicine scientists have laid bare a novel molecular mechanism responsible for the most important symptom of major depression: anhedonia, the loss of the ability to experience pleasure. While their study was conducted in mice, the brain circuit involved in this newly elucidated pathway is largely identical between rodents and humans, upping the odds that the findings point toward new therapies for depression and other disorders.
Additionally, opinion leaders hailed the study's inventive methodology, saying it may offer ...
Genetics Society of America's Genetics journal highlights for July 2012
2012-07-12
Bethesda, MD—July 11, 2012 – Listed below are the selected highlights for the July 2012 issue of the Genetics Society of America's journal, Genetics. The July issue is available online at www.genetics.org/content/current. Please credit Genetics, Vol. 191, JULY 2012, Copyright © 2012.
ISSUE HIGHLIGHTS
Increasing association mapping power and resolution in mouse genetic studies through the use of meta-analysis for structured populations, pp. 959-967
Nicholas A. Furlotte, Eun Yong Kang, Atila Van Nas, Charles R. Farber, Aldons J. Lusis, and Eleazar Eskin
Because ...
TGen method isolates biospecimens for treatment of kidney disease
2012-07-12
PHOENIX, Ariz. — July 11, 2012 — Researchers at the Translational Genomics Research Institute (TGen) have developed a method of isolating biospecimens that could lead to a less costly, less invasive and more accurate way of diagnosing chronic kidney disease, or CKD.
CKD is a major complication of diabetes, high blood pressure and a form of kidney disease known as glomerulonephritis, which is characterized by a progressive deterioration of the kidney's ability to filter waste from the blood.
TGen's customized procedure produced high amounts of protein-rich urinary exosomes, ...
Trigger for past rapid sea level rise discovered
2012-07-12
The cause of rapid sea level rise in the past has been found by scientists at the University of Bristol using climate and ice sheet models.
The process, named 'saddle-collapse', was found to be the cause of two rapid sea level rise events: the Meltwater pulse 1a (MWP1a) around 14,600 years ago and the '8,200 year' event. The research is published today in Nature.
Using a climate model, Dr Lauren Gregoire of Bristol's School of Geographical Sciences and colleagues unearthed the series of events that led to saddle-collapse in which domes of ice over North America ...
Mayo Clinic finds switch that lets early lung cancer grow unchecked
2012-07-12
JACKSONVILLE, Fla. — Cellular change thought to happen only in late-stage cancers to help tumors spread also occurs in early-stage lung cancer as a way to bypass growth controls, say researchers at Mayo Clinic in Florida. The finding, reported in the July 11 issue of Science Translational Medicine, represents a new understanding of the extent of transformation that lung cancer — and likely many other tumor types — undergo early in disease development, the scientists say. They add that the discovery also points to a potential strategy to halt this process, known as epithelial-mesenchymal ...
Global Budget Payment Model lowers medical spending, improves quality
2012-07-12
A new study suggests that global budgets for health care, an alternative to the traditional fee-for-service model of reimbursement, can slow the growth of medical spending and improve the quality of care for patients.
Researchers from Harvard Medical School's Department of Health Care Policy have analyzed claims data from Blue Cross Blue Shield of Massachusetts's Alternative Quality Contract (AQC), a global budget program in which 11 health care provider organizations were given a budget to care for patients who use BCBSMA insurance. Such a model contrasts with widely ...
OxyContin formula change has many abusers switching to heroin
2012-07-12
AUDIO:
A change in the formula of a frequently abused prescription painkiller seems to have convinced many drug abusers to switch to a substance that’s potentially more dangerous. Washington university researchers...
Click here for more information.
A change in the formula of the frequently abused prescription painkiller OxyContin has many abusers switching to a drug that is potentially more dangerous, according to researchers at Washington University School of Medicine in ...
First detailed timeline established for brain's descent into Alzheimer's
2012-07-12
Scientists have assembled the most detailed chronology to date of the human brain's long, slow slide into full-blown Alzheimer's disease.
The timeline, developed through research led by scientists at Washington University School of Medicine in St. Louis, appears July 11 in The New England Journal of Medicine.
As part of an international research partnership known as the Dominantly Inherited Alzheimer's Network (DIAN), scientists at Washington University and elsewhere evaluated a variety of pre-symptomatic markers of Alzheimer's disease in 128 subjects from families ...
Menopausal hormone therapy associated with increased blood pressure
2012-07-12
Menopausal hormone therapy use is associated with higher odds of high blood pressure, according to research published July 11 in the open access journal PLoS ONE. Longer hormone use was associated with further increased odds of high blood pressure, although this association decreased with subjects' ages.
The authors of the study, led by Joanne Lind of the University of Western Sydney, included 43,405 postmenopausal women in their study to identify the association.
As Dr. Lind explains, the study shows that "longer use of menopausal hormone therapy is associated with ...